Shares of biotechnology company Moderna (NASDAQ:MRNA)
fell 4.8% in the afternoon session after competitors Pfizer and BioNTech announced positive topline results for their updated 2025-2026 COVID-19 vaccine formula. The data from Pfizer and BioNTech showed their vaccine produced a robust immune response, signaling continued strong competition in the COVID-19 vaccine market.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Monday as we examine the latest happenings in today's session.
U.S. stocks edged higher Monday as investors positioned for a busy week of economic reports leading up to next week's Federal Reserve meeting. HOOD shares are climbing. Check the market position here.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Monday. Discover the gap up and gap down stocks in the S&P500 index.
Let's delve into the developments on the US markets one hour before the close of the markets on Friday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session.
Secretary for Health and Human Services, Robert F. Kennedy Jr., faced bipartisan backlash during a combative Senate hearing on Thursday, as both Republicans and Democrats criticized his controversial vaccine policies and the abrupt firing of Centers for Disease Control and Prevention Director Susan Monarez.
California, Oregon and Washington form regional vaccine alliance to counter federal guidance under Robert F. Kennedy Jr. as Florida eliminates state mandates.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Florida plans to end all statewide vaccine mandates, even those required for school attendance, framing the move as a defense of individual liberties, which has since received pushback from public health experts.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s return was flat while the S&P 500 climbed by 10.5%.
Sen. Elizabeth Warren (D-Mass.) is sounding the alarm on President Donald Trump's attempts at overhauling leadership at the Centers for Disease Control and Prevention, warning of risks to public health.
Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Moderna (NASDAQ:MRNA).
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 3.6% in the afternoon session after the company announced it received U.S. Food and Drug Administration (FDA) approval for its updated COVID-19 vaccines for the 2025-2026 season.
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing.
